Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment

The multi-kinase inhibitor sorafenib is clinically approved for the treatment of patients with advanced hepatocellular carcinoma (HCC). We previously reported that fibroblast growth factor 3 and 4 (FGF3/FGF4) amplification is a predictor of a response to sorafenib. This study aims to analyze the rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaibori, Masaki, Sakai, Kazuko, Ishizaki, Morihiko, Matsushima, Hideyuki, De Velasco, Marco A., Matsui, Kosuke, Iida, Hiroya, Kitade, Hiroaki, Kwon, A-Hon, Nagano, Hiroaki, Wada, Hiroshi, Haji, Seiji, Tsukamoto, Tadashi, Kanazawa, Akishige, Takeda, Yutaka, Takemura, Shigekazu, Kubo, Shoji, Nishio, Kazuto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226492/
https://www.ncbi.nlm.nih.gov/pubmed/27384874
http://dx.doi.org/10.18632/oncotarget.10077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226492/
https://www.ncbi.nlm.nih.gov/pubmed/27384874
http://dx.doi.org/10.18632/oncotarget.10077

Ejemplares similares